160 related articles for article (PubMed ID: 37584729)
21. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
[TBL] [Abstract][Full Text] [Related]
22. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
23. Quantitatively determined survivin expression levels are of prognostic value in human gliomas.
Chakravarti A; Noll E; Black PM; Finkelstein DF; Finkelstein DM; Dyson NJ; Loeffler JS
J Clin Oncol; 2002 Feb; 20(4):1063-8. PubMed ID: 11844831
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas.
Quaranta M; Divella R; Daniele A; Di Tardo S; Venneri MT; Lolli I; Troccoli G
Tumori; 2007; 93(3):275-80. PubMed ID: 17679463
[TBL] [Abstract][Full Text] [Related]
26. NAMPT, GRN, and SERPINE1 signature as predictor of disease progression and survival in gliomas.
Vachher M; Arora K; Burman A; Kumar B
J Cell Biochem; 2020 Apr; 121(4):3010-3023. PubMed ID: 31710121
[TBL] [Abstract][Full Text] [Related]
27. Cytokine Networks and Survivin Peptide-Specific Cellular Immune Responses Predict Improved Survival in Patients With Glioblastoma Multiforme.
Zhenjiang L; Rao M; Luo X; Valentini D; von Landenberg A; Meng Q; Sinclair G; Hoffmann N; Karbach J; Altmannsberger HM; Jäger E; Peredo IH; Dodoo E; Maeurer M
EBioMedicine; 2018 Jul; 33():49-56. PubMed ID: 30049387
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
[TBL] [Abstract][Full Text] [Related]
29. The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme.
Chambless LB; Kistka HM; Parker SL; Hassam-Malani L; McGirt MJ; Thompson RC
J Neurooncol; 2015 Jan; 121(2):359-64. PubMed ID: 25344883
[TBL] [Abstract][Full Text] [Related]
30. Intraoperative serum lactate is not a predictor of survival after glioblastoma surgery.
Cata JP; Bhavsar S; Hagan KB; Arunkumar R; Grasu R; Dang A; Carlson R; Arnold B; Popat K; Rao G; Potylchansky Y; Lipski I; Ratty S; Nguyen AT; McHugh T; Feng L; Rahlfs TF
J Clin Neurosci; 2017 Sep; 43():224-228. PubMed ID: 28601568
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma.
Tichy J; Spechtmeyer S; Mittelbronn M; Hattingen E; Rieger J; Senft C; Foerch C
J Neurooncol; 2016 Jan; 126(2):361-9. PubMed ID: 26518540
[TBL] [Abstract][Full Text] [Related]
32. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
[TBL] [Abstract][Full Text] [Related]
33. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of microRNA-21 expression in gliomas: a meta-analysis.
Li C; Sun J; Xiang Q; Liang Y; Zhao N; Zhang Z; Liu Q; Cui Y
J Neurooncol; 2016 Oct; 130(1):11-17. PubMed ID: 27531352
[TBL] [Abstract][Full Text] [Related]
35. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
36. Profiling of novel circulating microRNAs as a non-invasive biomarker in diagnosis and follow-up of high and low-grade gliomas.
Tabibkhooei A; Izadpanahi M; Arab A; Zare-Mirzaei A; Minaeian S; Rostami A; Mohsenian A
Clin Neurol Neurosurg; 2020 Mar; 190():105652. PubMed ID: 31896490
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma.
Strojnik T; Smigoc T; Lah TT
Anticancer Res; 2014 Jan; 34(1):339-47. PubMed ID: 24403485
[TBL] [Abstract][Full Text] [Related]
38. High Expression of Vimentin is Associated With Progression and a Poor Outcome in Glioblastoma.
Zhao J; Zhang L; Dong X; Liu L; Huo L; Chen H
Appl Immunohistochem Mol Morphol; 2018; 26(5):337-344. PubMed ID: 27556820
[TBL] [Abstract][Full Text] [Related]
39. The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma.
Gan C; Pierscianek D; El Hindy N; Ahmadipour Y; Keyvani K; Sure U; Zhu Y
BMC Cancer; 2020 Jul; 20(1):672. PubMed ID: 32680476
[TBL] [Abstract][Full Text] [Related]
40. Deep Sequencing of Small RNAs from Neurosurgical Extracellular Vesicles Substantiates miR-486-3p as a Circulating Biomarker that Distinguishes Glioblastoma from Lower-Grade Astrocytoma Patients.
Hallal S; Ebrahim Khani S; Wei H; Lee MYT; Sim HW; Sy J; Shivalingam B; Buckland ME; Alexander-Kaufman KL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
